Alembic Pharmaceuticals announced that the Company has receivedapproval from the US Food & Drug Administration (USFDA) for its Abbreviated NewDrug Application (ANDA) for Dorzolamide Hydrochloride Ophthalmic Solution USP,2%. The approved ANDA is therapeutically equivalent to the reference listed drugproduct (RLD) Trusopt Ophthalmic Solution, 2%, of Merck Sharp & Dohme Corp.Dorzolamide Hydrochloride Ophthalmic Solution is a carbonic anhydrase inhibitorindicated in the treatment of elevated intraocular pressure in patients with ocularhypertension or open-angle glaucoma.

Dorzolamide Hydrochloride Ophthalmic Solution USP, 2% has an estimated marketsize of US$ 35 million for twelve months ending December 2018 according to IQVIA